Beam Therapeutics (BEAM) Operating Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Expenses data on file, last reported at $139.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $139.0 million, up 34324.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (down 95.92% YoY), and the FY2025 annual result was -$243.7 million, down 150.86% from the prior year.
• Operating Expenses grew to $139.0 million in Q1 2026 per BEAM's latest filing, from -$251.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $468.7 million in Q4 2024 and troughed at -$251.0 million in Q4 2025.
• A 5-year average of $91.6 million and a median of $109.0 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses tumbled 301.16% in 2025, then jumped 34324.88% in 2026.
• A 5-year view of Operating Expenses shows it stood at $109.0 million in 2022, then surged by 68.16% to $183.3 million in 2023, then surged by 155.63% to $468.7 million in 2024, then sank by 153.55% to -$251.0 million in 2025, then surged by 155.37% to $139.0 million in 2026.
• Business Quant data shows BEAM's Operating Expenses at $139.0 million in Q1 2026, -$251.0 million in Q4 2025, and $136.5 million in Q3 2025.